Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Flinders University Of South Australia is engaged in the Biotechnology & Pharmaceuticals technology area, where it has 1 pending office action. This activity is contained within 1 distinct art unit. This suggests a highly targeted technical focus for the university's current patenting efforts. This concentration indicates a strategic emphasis on a particular technical niche within the Biotechnology & Pharmaceuticals sector.
The portfolio is being examined by 1 distinct examiner. OUSPENSKI, ILIA I is the busiest examiner for the university, handling 1 pending office action. This indicates that all current prosecution for the organization is being handled by this individual. The use of 1 distinct examiner suggests a centralized review process where all communication is directed through this official, which simplifies the management of the portfolio.
The data reveals a focused prosecution profile with 1 pending office action and 1 distinct examiner. For practitioners, the fact that 1 distinct art unit is involved signifies a singular path for the university's current intellectual property development. Since OUSPENSKI, ILIA I handles 1 pending office action, the outcome depends on this individual's interpretation of the claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779908 | METHODS AND PRODUCTS FOR REDUCING SIDE EFFECTS ASSOCIATED WITH USE OF IMMUNE AGONIST ANTIBODIES | OUSPENSKI, ILIA I | 77d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779908 | METHODS AND PRODUCTS FOR REDUCING SIDE EFFECTS ASSOCIATED WITH USE OF IMMUNE AGONIST ANTIBODIES | OUSPENSKI, ILIA I | 77d |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17779908 | METHODS AND PRODUCTS FOR REDUCING SIDE EFFECTS ASSOCIATED WITH USE OF IMMUNE AGONIST ANTIBODIES | OUSPENSKI, ILIA I | 1644 | §102§112 | Non-Final OA | 77d | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial